Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12424104 | 0.91 | KMT2A (0.52) | KMT2ARAB9ATSHRMAPK1SMN1; SMN2 | |
| SCHEMBL25880494 | 0.88 | HPGD (0.52) | KMT2ARAB9ATSHRMAPK1SMN1; SMN2 | |
| SCHEMBL1397958 | 0.83 | HTT (0.56) | KMT2ARAB9ATSHRSMN1; SMN2HTT | |
| SCHEMBL26259509 | 0.83 | KMT2A (0.62) | KMT2ARAB9ATSHRMAPK1NPC1 | |
| SCHEMBL26747693 | 0.82 | KMT2A (0.65) | KMT2ARAB9ATSHRMAPK1SMN1; SMN2 | |
| SCHEMBL7959922 | 0.80 | ALDH1A1 (0.50) | KMT2ARAB9ATSHRMAPK1SMN1; SMN2 | |
| SCHEMBL2757944 | 0.79 | KMT2A (0.50) | KMT2ARAB9ATSHRSMN1; SMN2NPC1 | |
| SCHEMBL23847771 | 0.79 | HTT (0.51) | KMT2ARAB9ATSHRSMN1; SMN2HTT | |
| SCHEMBL21389134 | 0.78 | KMT2A (0.46) | KMT2ARAB9ATSHRMAPK1HTT | |
| SCHEMBL22414091 | 0.78 | KMT2A (0.51) | KMT2ARAB9ATSHRSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023173132-A1 | ANTI-GLP1R ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-8003660-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-23 | — | — | US | disclosed |
| US-20070213315-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213315-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | KMT2A 2362/4885RAB9A 1944/4885TSHR 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.